Drug Trial Radar · NCT04511702
Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
191
Actual
Start
Oct 2, 2020
Primary completion
Jan 18, 2024
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.
Conditions
- Chronic Uncontrolled Gout
- Gout
- Uncontrolled Gout
Interventions
Pegloticase with MTXBiological
Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24Time frame: Day 1 to Week 24
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Orthopedic Physicians Alaska
Anchorage, Alaska
Arizona Arthritis & Rheumatology Research
Gilbert, Arizona
Arthritis & Rheumatology Research
Mesa, Arizona
Arizona Arthritis & Rheumatology Research
Phoenix, Arizona
Medvin Clinical Research
Covina, California
Amicis Research Center
Northridge, California
Providence Saint John's Health Center
Santa Monica, California
Medvin Clinical Research
Thousand Oaks, California
Medvin Clinical Research
Tujunga, California
University of Colorado Division of Rheumatology
Aurora, Colorado
Denver Arthritis Clinic
Denver, Colorado
Bradenton Research Center
Bradenton, Florida
Prohealth Research Center
Doral, Florida
LIFE Clinical Trials
Margate, Florida
D&H National Research Centers
Miami, Florida
IRIS Research and Development, LLC
Plantation, Florida
Napa Research Center
Pompano Beach, Florida
D&H Tamarac Research Centers
Tamarac, Florida
GCP Clinical Research
Tampa, Florida
ClinPro Research Solutions
Tampa, Florida
ForCare Clinical Research
Tampa, Florida
MedPharmics, LLC
Metairie, Louisiana
MD Medical Research
Oxon Hill, Maryland
Santa Fe Rheumatology
Santa Fe, New Mexico
Long Island Arthritis & Osteoporosis Care
Babylon, New York
Research Carolina Elite
Denver, North Carolina
PMG Research of Hickory, LLC
Hickory, North Carolina
Cape Fear Arthritis Care
Leland, North Carolina
PMG Research of Salisbury, LLC
Salisbury, North Carolina
Shelby Clinical Research, LLC
Shelby, North Carolina
Velocity Clinical Research Cincinnati
Cincinnati, Ohio
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Chattanooga Research & Medicine PLLC (CHARM)
Chattanooga, Tennessee
Abigail Rebecca Neiman, MD, PA
Houston, Texas
Pioneer Research Solutions Inc - Houston
Houston, Texas
Velocity Clinical Research, Salt Lake City
West Jordan, Utah
Western Washington Medical Group
Bothell, Washington
Arthritis Northwest
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.